Abstract
Dyslipidemia is a prominent feature of type 2 diabetes and insulin resistance that contributes to increased atherosclerosis and cardiovascular disease (CVD) risks under these conditions. Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have recently been developed and are approved for clinical use for treatment of type 2 diabetes. Besides improved glycemic control, other benefits are being increasingly appreciated, one of which is improved plasma lipid profile. This review aims to summarize the evidence and potential mechanism of such agents in humans in modulating fasting and postprandial lipoprotein metabolism.
Keywords: Apolipoprotein B-100, apolipoprotein B-48, cardiovascular disease, chylomicron, dipeptidyl peptidase-4, dyslipidemia, glucagon-like peptide-1, incretin-based therapies, triglyceride-rich lipoprotein, triglycerides, type 2 diabetes, very low-density lipoprotein
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System
Volume: 10 Issue: 4
Author(s): Changting Xiao, Satya Dash and Gary F. Lewis
Affiliation:
Keywords: Apolipoprotein B-100, apolipoprotein B-48, cardiovascular disease, chylomicron, dipeptidyl peptidase-4, dyslipidemia, glucagon-like peptide-1, incretin-based therapies, triglyceride-rich lipoprotein, triglycerides, type 2 diabetes, very low-density lipoprotein
Abstract: Dyslipidemia is a prominent feature of type 2 diabetes and insulin resistance that contributes to increased atherosclerosis and cardiovascular disease (CVD) risks under these conditions. Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have recently been developed and are approved for clinical use for treatment of type 2 diabetes. Besides improved glycemic control, other benefits are being increasingly appreciated, one of which is improved plasma lipid profile. This review aims to summarize the evidence and potential mechanism of such agents in humans in modulating fasting and postprandial lipoprotein metabolism.
Export Options
About this article
Cite this article as:
Xiao Changting, Dash Satya and F. Lewis Gary, Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530315
DOI https://dx.doi.org/10.2174/187152512803530315 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Drug Delivery Across the Blood-Brain Barrier
Current Drug Delivery Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Intraocular Inflammation and Systemic Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets